Payment overview · 2025
General Payments
$903.73
52 reported records · 15 companies
Healthcare provider profile · identity verified
Scott Hoffman, DO
Allopathic & Osteopathic Physicians|Internal Medicine · AKRON, OH · NPI 1740713593
Verified facts
What the public records show
CMS Open Payments records show Scott Hoffman, DO received $903.73 in general payments during 2025 across 52 reported records.
ABBVIE INC. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.88 | 19.4% | 16 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $124.33 | 13.8% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $82.54 | 9.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.59 | 9.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.04 | 8.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $64.44 | 7.1% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $52.43 | 5.8% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $48.18 | 5.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.05 | 4.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.75 | 4.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.60 | 3.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.29 | 3.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.28 | 3.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.28 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.05 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $903.73 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $130.57 | 11 | 2025 |
Source payment records
|
|||||
| EASYFUSE Normalized: easyfuse |
Device | Stryker Corporation | $124.33 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $82.54 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $72.04 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $64.44 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $52.43 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $51.65 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $48.18 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.31 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.31 | 5 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $41.05 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.75 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.60 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.94 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.28 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 212 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 128 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
45 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
212 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 483 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 328 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 270 | 85 |
| Omeprazole | Omeprazole | 266 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 241 | 76 |
| Losartan Potassium | Losartan Potassium | 239 | 73 |
| Lisinopril | Lisinopril | 230 | 86 |
| Eliquis | Apixaban | 212 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 65 |
| Furosemide | Furosemide | 196 | 64 |
| Gabapentin | Gabapentin | 195 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 41 |
| Jardiance | Empagliflozin | 128 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 57 |
| Carvedilol | Carvedilol | 119 | 39 |
| Metformin Hcl Er | Metformin Hcl | 113 | 40 |
| Metformin Hcl | Metformin Hcl | 110 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 105 | 24 |
| Potassium Chloride | Potassium Chloride | 104 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 33 |
| Sertraline Hcl | Sertraline Hcl | 102 | 30 |
| Buspirone Hcl | Buspirone Hcl | 101 | 24 |
| Ezetimibe | Ezetimibe | 95 | 31 |
| Simvastatin | Simvastatin | 92 | 31 |
| Mirtazapine | Mirtazapine | 91 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 31 |
| Trazodone Hcl | Trazodone Hcl | 91 | 27 |
| Famotidine | Famotidine | 84 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 30 |
| Baclofen | Baclofen | 80 | 14 |
| Levetiracetam | Levetiracetam | 78 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 25 |
| Meloxicam | Meloxicam | 75 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 28 |
| Divalproex Sodium | Divalproex Sodium | 70 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 24 |
| Pregabalin | Pregabalin | 69 | 21 |
| Allopurinol | Allopurinol | 67 | 25 |
| Tramadol Hcl | Tramadol Hcl | 67 | 27 |
| Celecoxib | Celecoxib | 62 | 27 |
| Glipizide | Glipizide | 62 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 22 |
| Topiramate | Topiramate | 58 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 16 |
| Donepezil Hcl | Donepezil Hcl | 53 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 40 |
| Cephalexin | Cephalexin | 48 | 22 |
| Montelukast Sodium | Montelukast Sodium | 48 | 19 |
| Olanzapine | Olanzapine | 48 | suppressed |
| Prednisone | Prednisone | 48 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 37 |
| Lorazepam | Lorazepam | 47 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 20 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 45 | 45 |
| Bupropion Xl | Bupropion Hcl | 45 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 14 |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Nystatin | Nystatin | 42 | 18 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 15 |
| Lovastatin | Lovastatin | 39 | 15 |
| Alendronate Sodium | Alendronate Sodium | 37 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 12 |
| Colchicine | Colchicine | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 22 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Azithromycin | Azithromycin | 30 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 17 |
| Potassium Citrate Er | Potassium Citrate | 28 | suppressed |
| Finasteride | Finasteride | 27 | 11 |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Ozempic | Semaglutide | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Fenofibrate | Fenofibrate | 25 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Cefdinir | Cefdinir | 24 | 19 |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 14 |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Sodium Bicarbonate | Sodium Bicarbonate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Epinephrine | Epinephrine | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Klor-Con | Potassium Chloride | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $903.73 · 52 records | ABBVIE INC. | AUSTEDO XR, Auvelity, Cologuard Collection Kit, EASYFUSE, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, NEXLETOL, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, Rybelsus, TRELEGY ELLIPTA, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error